CROs/Service Providers

RCSI, Almac partner on target therapy-resistant cancer tumors

Wednesday, February 15, 2017

RCSI (Royal College of Surgeons in Ireland) and Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, have announced a major research collaboration that aims to gain a new understanding of how to target tumor cells that are resistant to cancer therapies and cause cancer to spread to other parts of the body. The project will explore the potential of a drug, based on initial research by RCSI’s Professor Tracy Robson and developed by Almac Discovery, which is currently undergoing a phase I dose escalation trial for patients with solid tumors. It is expected that the trial will be expanded in a biomarker selected patient population within ovarian cancer, however the drug, ALM201, has the potential to treat a range of other cancers.

[Read More]

Clintec launches new brand and website design

Wednesday, February 15, 2017

Clintec has launched its new brand identity, reflected in their newly created website. This in part marks Clintec’s 20th anniversary and the achievement of significant milestones following another year of substantial growth, together with a succession of key appointments that have enhanced the global leadership team.

[Read More]

Beaufort receives ISO 9001:2015 certification

Tuesday, February 14, 2017

Beaufort, a CRO and consultancy, has obtained ISO 9001:2015 certification. The certification demonstrates that Beaufort provides consistently good quality services to the life sciences industry in its clinical research, regulatory affairs, quality and staffing solutions.

[Read More]

Report: Global clinical trial service market will reach $64B by 2020

Wednesday, February 8, 2017

Research and Markets research forecasts that the global clinical trial service market will likely reach more than $64 billion by 2020, up from $38.4 billion at present, representing a CAGR of 9% between 2015 and 2020. By 2020 the average clinical trial outsourcing penetration will likely reach around 72%. In other words, by then close to three fourths of clinical trials will likely be performed by professional CROs.

[Read More]

Quotient Clinical acquires SeaView Research

Wednesday, February 8, 2017

Quotient Clinical, an early phase drug development services provider, has acquired SeaView Research, expanding its operations into the U.S. The acquisition combines Quotient and SeaView’s complementary customer portfolios, and strengthens the early phase clinical experience of the combined business, enabling the company to deliver a broader set of services.

[Read More]

Chiltern expands in Bangalore, India

Wednesday, February 1, 2017

Chiltern, a global CRO, has announced the opening of its new process and technology center in Bangalore, India. The new office is a direct result of the company’s continued success and fulfills a need to further enhance its global data capabilities.

[Read More]

Porton USA to acquire J-STAR Research

Monday, January 30, 2017

Porton Fine Chemicals, a China-based contract development and manufacturing organization (CDMO) serving the global pharmaceutical industry, has announced that Porton USA, a wholly-owned subsidiary of Porton, has entered into a stock purchase agreement with the shareholders of J-STAR Research, a contract chemistry organization based in South Plainfield, New Jersey, under which PTC will acquire J-STAR from its shareholders for no more than $26 million in cash.

[Read More]